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Background: Use of antidepressants is the gold standard therapy for major depression. 
However, despite the large number of commercially available antidepressant drugs there are 
several differences among them in efficacy, tolerability, and cost-effectiveness. In addition the 
optimal augmentation strategy is still not clear when dealing with treatment-resistant depression, 
a condition that affects 15% to 40% of depressed patients.
Methods: We therefore reviewed the main characteristics of these drugs regarding their efficacy, 
tolerability, side effects and cost-effectiveness, by accessing all meta-analyses and systematic 
reviews published from 2004 to 2009. In addition, we reviewed the augmentation strategy 
of associated antidepressants with neurostimulation therapies (such as transcranial magnetic 
stimulation [TMS] and transcranial direct current stimulation [tDCS]). A search was undertaken 
in MEDLINE, Web of Science, Cochrane, and Scielo databases. We included: 21 meta-analyses 
of antidepressant trials, 15 neurostimulation clinical trials and 8 studies of pharmacoeconomics. 
We then performed a comprehensive review on these articles.
Results and Conclusion: Although recent meta-analyses suggest sertraline and escitalopram 
might have increased efficacy/tolerability, other studies and large pragmatic trials have not found 
these to be superior to other antidepressant drugs. Also, we did not identify any superior drug 
in terms of cost-effectiveness due to the different designs observed among pharmacoecomics 
studies. Side effects such as sexual dysfunction, gastrointestinal problems and weight gain were 
common causes of discontinuation. Tolerability was an important issue for novel neurostimulation 
interventions, such as TMS and tDCS. These therapies might be interesting augmentation strategies, 
considering their benign profile of side effects, if proper safety parameters are adopted. 
Keywords: acute depressive episode, pharmacological interventions, combined interventions
Introduction
The use of pharmacotherapy in psychiatry started in the beginning of the 19th century 
with the introduction of morphine, lithium, potassium bromide, and chloral hydrate for 
the treatment of some mental conditions.1 However, “modern” psychopharmacology – 
as a field linking the advances in neuropharmacology, psychiatric nosology and clinical 
research2 – dates from the late 1950s, when drugs such as chlorpromazine, haloperidol, 
reserpine, and imipramine started to be used in hospitalized patients and, later on, in 
other psychiatric settings.3 Since then numerous psychopharmacological drugs have 
been developed and introduced into clinical practise. The intensive development of 
psychopharmacology has resulted in the development of different agents that may 
be divided into four major classes of antidepressant drugs: tricyclic antidepressants 
(TCAs); monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake Therapeutics and Clinical Risk Management 2009:5 898
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inhibitors (SSRIs); and serotonin-norepinephrine reuptake 
inhibitors (SNRIs) in addition to a variety of other miscel-
laneous antidepressant drugs4,5 (Table 1).
The large number of available antidepressants is not 
only a result of market forces, but also a result of varied 
efficacy, differential pricing, and especially adverse effects 
of the different available drugs. For example, although 
older (TCAs, MAOIs) and newer (SSRIs, SNRIs) antide-
pressants might not differ substantially in efficacy,6,7 the use 
of older antidepressants have generally decreased because 
they are associated with increased side effects and toxic-
ity.8 Even for newer antidepressants, there are important 
differences in side effects across the range of available 
drugs. Additonally more intense side effects are associated 
with higher dropout rates.9 A similar issue is observed for 
efficacy as there is still no consensus on which are the most 
effective antidepressant drugs, for example, while one meta-
analysis suggests that newer SNRIs have greater efficacy 
than SSRIs,10 other studies suggest that mirtazapine and 
milnacipran have similar efficacy to modern SSRIs.11,12 Stud-
ies from the 1980s showed MAOIs to have greater efficacy 
than TCAs for treatment-resistant depression.13,14 Here the 
study population is an important factor in explaining these 
differences.
Another critical issue when making comparisons across 
antidepressants is the methodological issues involved in 
clinical trials that can affect the interpretation of results 
such as:
a)  The placebo response of MDD clinical trials is very 
high15,16 which might lead to a ceiling effect to the truly 
antidepressant response;17
b)  Placebo response has also grown through time, thereby 
favoring new trials to fail;18,19
c)  Differences in trial design when comparing against pla-
cebo or against active drug modify drug response;20
d)  Major depression, being a heterogeneous construct 
of disease,17 increases group variance, decreasing 
internal validity and leading results towards the null 
hypothesis, and;
e)  Head-to-head comparisons are often designed as 
noninferiority studies – ie, studies testing the hypothesis 
that one drug does not “significantly differ” from others – 
since the cut-off point of significance (ie, the difference 
that is acceptable when considering there is no clinical 
difference) in such studies is quite arbitrary. Therefore 
it is difficult to draw valid conclusions regarding the 
efficacy, tolerability and cost-effectiveness of such 
drugs.
Besides the differences in efficacy and side effects, the 
other main issue is when treatments with antidepressants fail. 
In this case, several strategies have been proposed, such as 
dose uptitration, switching, or combining antidepressants, 
psychotherapy, and augmentation with nonantidepressant 
drugs.21 However, the use of multiple medications also 
increases the risk of side effects, drug–drug interactions, 
and overall costs of treatment. Additionally, it is unclear 
how long the add-on treatment should be maintained, if at 
all, after the remission of depression as this can prolong its 
use beyond necessary.22,23
An alternative is to combine antidepressants with 
neurostimulation therapies as augmentation strategies, such 
as electroconvulsive therapy (ECT), repetitive transcranial 
magnetic stimulation (rTMS), and transcranial direct 
current stimulation (tDCS)24 to hasten remission. For 
example, a recent sham-controlled trial showed that active 
rTMS hastened the effects of venlafaxine, escitalopram 
and sertraline.25 Moreover, an ECT meta-analysis revealed 
its efficacy in treating acute depression when combined 
to antidepressants.26 Neurostimulation techniques have 
been increasingly studied in the past decades as an aug-
mentation alternative for treatment-resistant depression.27 
However, the benign profile of adverse events and inva-
siveness of newer techniques such as tDCS and rTMS has 
also stimulated clinical trials in less refractory patients. 
Table 1 Summary of antidepressant classes and common brands
MAOIs SSRIs SNRIs TCAs Others
Tranylcypromine Fluoxetine venlafaxine Amitriptyline Bupropion
Phenelzine Paroxetine Duloxetine Clomipramine Mirtazapine
isocarboxazid Sertraline Milnacipran imipramine Reboxetine
Transdermal selegine Fluvoxamine Desvenlafaxine Nortriptyline Trazodone
Citalopram Nefazodone
escitalopram
Abbreviations: TCAs, tricyclic antidepressants; MAOis, monoamine oxidase inhibitors; SSRis, selective serotonin reuptake inhibitors; SNRis, serotonin-norepinephrine 
reuptake inhibitors.Therapeutics and Clinical Risk Management 2009:5 899
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Repetitive transcranial magnetic stimulation is being 
increasingly studied in neuropsychiatric disorders as it 
generates a strong magnetic field that induces an electric 
current within the brain in order to modulate a specific 
cortical brain area.28 Recently, rTMS has been approved 
in the US for treatment of patients with major depression 
who have not responded to a single antidepressant drug 
trial.29 Additionally rTMS has also been approved for 
clinical use in other countries such as Canada, Italy, Israel, 
and Brazil. Transcranial direct current stimulation induces 
a weak direct current in the cortex, and depending on 
the duration and polarity of stimulation, it can induce an 
increase or decrease of cortical excitability.30 Initial tDCS 
studies show promising results in recent clinical trials for 
major depression.31
The aim this comprehensive review is therefore 
two-fold:
a)  To summarize the main aspects (efficacy, safety, 
tolerability) the physician should consider when choosing 
an antidepressant for the acute depressive episode;
b)  To review the use of neurostimulation treatments as 
nonpharmacological alternatives for augmentation 
strategies with antidepressants for the acute depressive 
episode.
Finally, it should be underscored that in this review we 
use the accepted definitions standard applied in clinical 
research, ie, the acute phase usually lasts 6 to 8 weeks and 
ends with remission of symptoms, (usually indexed as a 
Hamilton Depressive Rating Scale  8), thus indicating a 
pre-morbid levels of function. Response is defined as the 
reduction of the depressive symptoms (usually indexed in 
more than 50% of the baseline scores of a depressive mood 
scale). The continuation phase lasts 4 to 9 months, in which 
treatment is continued to prevent re-emergence of symptoms 
(relapse), followed by the maintenance phase that lasts 
indefinitely, or until the patient presents a new depressive 
episode (recurrence).32
Methods
Literature search
We searched for articles published in the last 5 years (2004 
to May 2009, including online articles published “ahead of 
print”) in the following databases: MEDLINE, Web of Science, 
Cochrane, and Scielo. We used the following keywords: “meta-
analysis” or “systematic review”; “antidepressant drugs”; and 
“major depression” or “depression” or “major depressive 
disorder”. We also performed additional searches with the 
keywords: “transcranial magnetic stimulation” or “direct 
current stimulation” or “ECT” and “antidepressants” to assess 
the efficacy of neurostimulation augmentation strategies.
Selection criteria for antidepressants: We chose to ana-
lyze meta-analysis studies and systematic reviews instead of 
individual clinical trials because:
a)  Several meta-analyses of efficacy and tolerability have 
already been performed in this short period of time, thus 
we chose to review these meta-analyses rather than per-
forming another meta-analysis on the topic and generating 
redundant data;33–35
b)  Since the goal of this paper is to provide an overview of effi-
cacy and acceptability of antidepressants, we chose to identify 
the articles summarizing the evidence found in clinical trials, 
thus prioritizing a comprehensive review of such evidence.
Focusing on meta-analyses allowed us to restrict our 
publication search time period to the last 5 years, as meta-
analyses are able to assess the evidence of prior trials. The 
eligibility criteria were:
a)  Manuscripts written in English;
b)  For efficacy studies – meta-analyses that compared 
several antidepressant drugs (we did not include meta-
analyses of an specific drug);
Table 2 Summary of meta-analyses that compared antidepressants vs placebo
Author   Antidepressant Condition Studies  
(subjects)
Main results Comments
Chen41 All PSD 16 (1320) eS = 0.23 for AD  
(response)
Longer treatments might   
be more effective
Nelson40 2nd gen Geriatric 10 (4165) ORs = 1.4 vs placebo  
(remission)
Significant heterogeneity  
of outcomes
Arroll43 All Prim. care 15 (2753) NNT = 4–6 vs placebo  
(remission)
Both TCA and SSRi were   
effective
Kirsch42 2nd gen (4 AD) Adult 35 (5133) d = 0.32 (mood score) included unpublished  
studies
Abbreviations: OR, odds ratio; RR, relative risk; eS, effect size;   AD, antidepressants; NNT, number needed to treat; d, Cohen’s d (a measure of effect size); TCA, tricyclic 
antidepressants; SSRi, selective serotonin reuptake inhibitors PSD, post-stroke depression.Therapeutics and Clinical Risk Management 2009:5 900
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c)  For safety studies – meta-analyses of adverse effects, 
incidence of suicide and tolerability;
d)  Other meta-analyses on pharmacoeconomics and cost-
effectiveness.
The selection criteria for neurostimulation interventions 
were controlled trials in which a non-pharmacological was 
combined with a pharmacological therapy – ie, an (active 
device + drug) vs (sham device + drug) trial. Eligibility 
criteria were:
a)  Manuscripts written in English;
b)  Efficacy and safety studies: double-blinded, sham-
controlled, randomized trials;
c)  Cost-effectiveness: pharmacoeconomics analysis.
Finally, other neurostimulation techniques, such as deep 
brain stimulation (DBS) and vagus nerve stimulation (VNS) 
are not covered in this study because they are invasive surgi-
cal techniques associated with an increased risk of adverse 
effects. More specifically the purpose of our review is to 
assess neurostimulation strategies that can be more straight-
forwardly applied during an acute depressive episode.
Results
For antidepressant drugs
Using the keywords and time limits defined above, we were 
able to find 111 records in MEDLINE. Of these, 90 references 
were excluded because
a)  Other articles formats (letters to the editor, clinical trials, 
comments, qualitative reviews);
b)  Meta-analyses focusing on one specific antidepressant 
drug, nonantidepressant drugs, or other methodological 
approaches.
Therefore, 21 articles were reviewed.
For neurostimulation interventions
There were 123 rTMS records found and those deemed 
unsuitable were excluded for similar reasons to those 
above. Thirteen articles were reviewed for efficacy and 1 for 
pharmacoeconomics analysis.
For tDCS, 25 records were found though only 4 clinical 
studies were initially included. However, 3 of these,36–38 used 
medication-free patients and the remaining one was open 
label.39 No pharmacoeconomics analyses were identified 
for this group.
For ECT, of 36 records found 33 were excluded, (open-
label, naturalistic, retrospective studies), leaving 1 clinical 
trial and 2 pharmacoeconomics studies that were included.
Efficacy of new-generation antidepressants 
in prophylaxis, maintenance and treatment-
resistant depression
We identified 9 studies focusing on the acute-term efficacy 
of antidepressants. Four meta-analyses were performed: 
1 in late-life depression40 1 in post-stroke depression,41 and 
2 in adult patients.42,43 All these compared the the difference 
in drug–placebo response at end-of-treatment, which was 
between 4 and 8 weeks.
The meta-analysis on post-stroke depression41 assessed 
16 randomized clinical trials and showed that depression 
response was superior in patients using antidepressants 
(65%) when compared to those using placebo (44%), 12 of 
the 16 studies used SSRIs. Subgroup analyses showed a 
significant time effect in antidepressant group, ie, increased 
duration of treatment response and remission rates. A second 
meta-analysis focused on second-generation antidepressants 
in late-life depression.40 Ten randomized clinical trials were 
analyzed which indicated that antidepressants are signifi-
cantly superior to placebo regarding response (odds ratio 
[OR] = 1.4, 95% confidence interval [CI] = 1.24-1.57) and 
remission (OR = 1.22, 95% CI = 1.05-1.42) rates. There was 
also a time effect identified in the antidepressant group.
Two meta-analyses compared antidepressants vs placebo 
in adult patients. In 2005, a meta-analysis of depression in 
primary care43 analyzed 15 studies (3 on SSRIs) showing 
response rates from 56% to 60% for antidepressants vs 
42% to 47% for placebo. However, most trials were of low 
methodological quality. A further meta-analysis published 
Table 3 Summary of meta-analyses that compared antidepressants vs “new” antidepressants
Author Antidepressant Studies (number  
of patients)
Main results Comments
Hansen44 “New” AD 46 (N/A) No difference in AD efficacy Quantitative analyses  
were not done
Montgomery45 6 AD N/A (N/A) eSC probably superior Not a systematic review
Cipriani33 2nd gen (12 AD) 117 (25928) eSC and SeRT superior Direct/indirect comparisons
Notes: “New” AD refers to new antidepressants, such as selective serotonin reuptake inhibitors (SSRi).
Abbreviations: eSC, escitalopram; SeRT, sertraline.Therapeutics and Clinical Risk Management 2009:5 901
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in 200815 reviewed 35 published and unpublished trials 
comparing seven new-generation antidepressant drugs against 
placebo. The authors concluded that although a statistical dif-
ference for mean drug–placebo response was obtained (1.8 on 
Hamilton Depression Rating Scale), it did not reach the 3-point 
difference that translates into clinical significance. Moreover, 
meta-regression analysis showed that antidepressant drugs 
only achieved clinical significance when baseline severity 
scores were high (corresponding to severe depression).
Three meta-analyses involved drug-drug trials that perform 
direct and indirect comparisons for efficacy, safety and other 
outcomes. Hansen and colleagues44 assessed and reviewed 
46 head-to-head trials comparing one new-generation anti-
depressant to another, concluding “second-generation antide-
pressants probably do not differ substantially for treatment of 
major depressive disorder”. However, only direct comparisons 
(meaning results from a head-to-head clinical trials) were 
performed, which might limit the generality of the results as 
only few comparisons could be made. The meta-analysis of 
Montgomery et al45 also performed direct head-to-head com-
parisons, concluding that “only a very few antidepressants are 
shown to be more effective than others”, while pointing out 
for a “possible superiority” for milnacipran and clomipramine, 
a “probable superiority” for venlafaxine, and a “definite 
superiority” for escitalopram. However, only direct comparisons 
were performed and these too might limit the generality of both 
meta-analyses. Finally, Cipriani et al33 performed a meta-analysis 
comparing 12 new-generation antidepressants (buproprion, 
citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, 
milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, 
and venlafaxine) for efficacy and acceptability by review-
ing 117 controlled trials and performing direct and indirect 
comparisons. The authors’ conclusion was that the antidepres-
sants mirtazapine, escitalopram, venlafaxine, and sertraline were 
significantly more effective than the others, and that escitalopram 
and sertraline showed the best profile of acceptability.
Efficacy of new-generation antidepressants for major 
depression in other contexts (prophylaxis, prevention of 
relapse and recurrence, treatment-resistant depression).
We identified 4 meta-analyses on the above topic.46–49 
Two meta-analyses focused on treatment discontinuation 
and risk of relapse. One of these46 reviewed 5 clinical trials 
in which 1009 patients were chosen at random to receive a 
full antidepressant dose or a reduced dose (generally half of 
antidepressant dose). After 8 to 12 weeks, the relative risk of 
relapse using lower doses compared to the full dose, was 1.62 
(95% CI = 1.23-2.15). The other meta-analysis48 focused on 
comparing by antidepressant class (SSRI vs TCA) and the 
degree of refractoriness (single major depression episode vs 
recurrent depression). Thirty trials, enrolling 4890 patients, 
were reviewed. Results showed that the use of antidepressants, 
regardless of their class, reduces relapse risk over 1 year of 
follow up (OR = 0.24 for SSRI, OR = 0.29 for TCI). Patients 
with recurrent depression have an increased risk of relapse 
than those with a single major depression episode. One meta-
analysis47 looked for evidence of antidepressant prophylaxis for 
post-stroke depression. In reviewing 10 clinical trials in which 
this intervention was performed in nondepressed patients 
after a stroke. The pooled analysis showed that the occur-
rence rate of depression in patients using antidepressant was 
12.5%, against a significant difference of 29.17% in patients 
in control group, which suggests the use antidepressants in 
non-depressed patients after a stroke might be worthwhile. The 
meta-analysis study of Hansen et al49 reviewed evidence of 
the efficacy of new-generation antidepressants in preventing 
major depression relapse involving four head-to-head trials 
and 23 placebo-controlled trials. The study found that although 
no differences were observed in comparative trials, in placebo 
trials the NNT is 5 (95% CI 4–6) for preventing relapse and 
recurrence of major depression episodes.
New-generation antidepressants – side 
effects and tolerability
Seven meta-analyses reviewed the safety, tolerability, and 
some side effects related to antidepressant use.33,44,50–54 One 
meta-analysis51 reviewed specifically the safety of using 
antidepressants in breast-feeding women by analyzing stud-
ies that measured maternal and infant plasma levels, together 
with breast milk levels. Fifty-seven studies were included 
which tested amitryptiline, clomipramine, dothiepin, imip-
ramine, buproprione, citalopram, fluvoxamine, fluxoetine, 
nortriptlyine, sertraline, and nefazodone. The conclusion 
was that nortriptyline, paroxetine, and sertraline might be the 
preferred choices in these patients, while citalopram dosage 
should be reduced as this drug produced elevated plasma 
levels in 17% of infants. The meta-analysis understaken 
by McIntyre et al50 reviewed antidepressant effects on lipid 
metabolism and found that drugs related to weight gain (tryci-
clics, mirtazapine) are more likely to induce changes in lipid 
profile than weight neutral drugs (buproprion, venlafaxine, 
duloxetine). However, the meta-analysis was unable to assess 
whether or not there is a weight-independent effect related 
to some antidepressants. The more recent meta-analysis of 
Serretti et al54 demonstrated that the risks and rates of sexual 
dysfunction were highest in the antidepressants sertraline, 
citalopram, fluoxetine, paroxetine, and venlafaxine followed Therapeutics and Clinical Risk Management 2009:5 902
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by fluovoxamine, escitalopram, duloxetine, phenelzine, and 
imipramine, while agomelatine, mirtazapine, bupropion, 
amineptine, and nefazodone showed rates similar or inferior 
to placebo.
Four other meta-analyses focused on the general harms 
and safety of new-generation antidepressants. Hanset et al44 
found that venlafaxine produced significantly more nausea/
vomiting and dizziness than the other antidepressants, with 
a mean incidence of 31% and 16%, respectively. One study 
suggested that this drug was also associated with increased 
blood pressure, while bupropion users showed an increased 
incidence of headache (27%) and insomnia (16%). Other 
important side effects, such as weight gain and sexual side 
effects, were not addressed because of inadequate reporting 
and great variability in assessment methods. Gartlehner and 
colleagues performed 2 meta-analyses52,53 including 203 and 
104 studies and found that: venlafaxine had the highest 
rates of discontinuation, probably because of increased 
incidence of nausea and vomiting, while sertraline had the 
highest incidence of diarrhea, mirtazapine and paroxetine 
were associated with greater weight gain, and trazodone 
with increased somnolence. For sexual dysfunction rates, 
buproprion presented significantly less, while paroxetine 
presented significantly more, compared to other second-
generation antidepressants. Finally, Cipriani et al33 aimed to 
rank 12 new-generation antidepressants for their efficacy and 
tolerability (measured by dropout rate) with data extracted 
from 117 trials and observed that escitalopram and sertraline 
were tolerated significantly more than venlafaxine and other 
SSRIs, Both these drugs showed the potential for being 
first-line treatment as they showed increased efficacy over 
venlafaxine and other SSRIs. In addition sertraline demon-
strably had the most favorable balance between benefits, 
acceptability, and acquisition costs.
Finally, we identified no meta-analyses focusing on 
antidepressants compliance (ie, treatment adherence in 
clinical practice that is influenced by a combination of side 
effects, tolerability, individual characteristics, patient–
physician relationship and treatment costs), therefore it is 
still not clear whether or not antidepressant drugs differ 
in compliance.
Safety of new-generation antidepressants –   
the risk and rates of suicide
The meta-analysis study of Hammad et al55 assessed individ-
ual patient data from 207 trials, for a total of 40,028 patients 
with major depression. They identified 21 cases of 
suicide. In placebo-controlled trials there were 5 suicides 
(1.5/1000 person-years), while in active-only trials there 
were 16 suicides (11.1/1000 person-years). Although Poisson 
regression analysis indicated this was not a significant differ-
ence the authors concluded that with such a small number of 
suicides any increased suicide risk in patients taking antide-
pressant drugs cannot be definitively excluded.
Studies of pharmacoeconomics  
and cost-effectiveness
Five meta-analyses were included,56–60 focusing on the phar-
macoeconomics of escitalopram, sertraline and the budget-
impact of SSRIs, SNRIs, and TCA in Brazil, Colombia, the 
UK, and worldwide. In 2004, a cost-effectiveness analysis 
of escitalopram compared the drug against other SSRIs and 
venlafaxine, concluding that escitalopram costs were sys-
tematically lower than the other drugs.60 Another analysis 
performed in the same year compared the cost of SNRI vs 
SSRIs vs TCA in the UK. This suggested that venlafaxine 
might be a cost-effective first-line drug compared with the 
SSRIs and TCAs.59 In 2005, a cost-effectiveness review 
enrolled several studies performed in nine countries compar-
ing SNRIs vs TCAs vs SSRIs and concluded that the higher 
initial cost of SNRI is probably compensated by higher suc-
cess rates of drugs of this class.58 In 2007, a budget-impact 
analysis to evaluate the impact of SNRI introduction in the 
Brazilian national drug-free formulary used an existing 
decision-tree analysis and concluded that, from a public 
healthcare perspective, there are no significant difference 
in cost-effectiveness between the drug classes of SNRIs, 
SSRIs, and TCAs.56 The same authors performed another 
budget-impact analysis to evaluate the cost-effectiveness of 
amitriptyline, fluoxetine and venlafaxine in Colombia and 
found that amitriptyline was more cost-effective compared 
to the other two drugs (venlafaxine costs were evaluated 
for the brand-name product, as generics were not currently 
available in that country).57
Neurostimulation augmentations 
strategies for the acute depressive 
disorder
electroconvulsive therapy (eCT)
Sackeim et al61 performed a multi-center trial that enrolled 
319 patients with treatment-resistant, severe depression in a 
2 × 3 factorial design trial (patients received either unilateral 
or bilateral ECT vs nortriptyline or venlafaxine or placebo). 
Although all groups were effective, post-hoc analysis showed 
the association of nortriptyline with ECT to be superior of Therapeutics and Clinical Risk Management 2009:5 903
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placebo with ECT (the group venlafaxine with ECT did not 
differ from others).
Two studies assessed the pharmacoeconomics of ECT. 
Greenhalgh et al62 reviewed the evidence of clinical and cost-
effectiveness of ECT for depressive illness, schizophrenia, 
catatonia, and mania. For major depression, they concluded 
ECT to be probably more effective than pharmacotherapy 
in the short term; that TCAs might improve ECT effects 
during the treatment; and that there is limited evidence of 
long-term efficacy of ECT and the impact of ECT on suicide 
and all-cause mortality. They concluded that there is still 
much uncertainty whether ECT is a cost-effective treatment. 
McLoughlin et al63 performed a pragmatic randomized trial 
to compare rTMS vs ECT with 6-month follow-up, evaluat-
ing depression improvement and gains in quality-adjusted 
life-years (QALYs). They concluded that ECT was superior 
to rTMS at end-of-treatment (3 weeks) but not at follow-up 
(6 months). Also, the overall treatment costs of both therapies 
were similar as well as QALYs improvement.
Transcranial direct current  
stimulation (tDCS)
The trial of Loo et al64 enrolled 40 depressed patients that had 
already failed 1 antidepressant trial to receive either active 
or sham tDCS (5 sessions, 1 mA, anodal on the left). Their 
study failed to prove any significant differences between 
active and sham treatment groups.
Repetitive transcranial magnetic 
stimulation (rTMS)
Nine studies tested the efficacy of rTMS as an augmenta-
tion strategy,65–73 ie, patients already on antidepressant 
drugs (mostly with treatment-resistant depression) that used 
rTMS to ameliorate of symptoms. In 2005, Su et al65 tested 
the efficacy of 2-week fast rTMS in 30 treatment-resistant 
depression patients and found a statistically significant supe-
rior response rate in the active group (60% vs 10%). Rossini 
et al66 in the same year, with similar design (2-week fast rTMS 
in treatment-resistant depression), enrolled 50 patients. Two 
parameters of stimulation were tested (80% vs 100% intensity 
of motor threshold [MT]). The response rates were 61%, 
27%, and 6.2% in 100% MT, 80% MT, and sham; the 80% 
MT group did not differ from the placebo group.
In 2006, Avery et al67 tested in 68 treatment-resistant 
depression patients with real (3-week, fast rTMS) or sham 
rTMS. They found superior response and remission rates 
in the active group (30.6% vs 6.1%, P  0.01; 20% vs 3%, 
P  0.3, respectively). Fitzgerald et al68 conducted a 6-week 
trial in 50 patients with treatment-resistant depression, 
combining bilateral stimulation in the active group against a 
sham group. They demonstrated there was greater response 
and remission rates in the active groups (44% vs 8% and 
36% vs zero, respectively). Garcia-Toro et al69 compared 
bilateral stimulation with SPECT-targeted stimulation and a 
sham group. In a sample of 30 patients they found both active 
treatments to be superior (improvement of 23% vs 32% vs 
5%, respectively). In 2007, Anderson et al70 tested the effi-
cacy of fast rTMS 3 times a week in a sample of 29 treat-
ment-resistant patients and found response rates of 55% in 
the active sample and 7% in the placebo group (P  0.05). 
In a small trial, Bortolomasi et al71 tested the efficacy of 
fast rTMS vs sham in 19 patients. They also found supe-
rior improvement in the active group. Loo et al72 tested the 
efficacy and safety of twice-daily rTMS over 2 weeks in 38 
treatment-resistant depression patients, observing a greater 
improvement in the active patients than in the sham group at 
end-of-treatment (2-week) and follow-up (6-week). Finally, 
Mogg et al73 studied the effects of long-term (4-month) treat-
ment of rTMS, randomizing 59 patients to receive either 
10 sessions of fast rTMS or sham; however there was no 
significant difference between groups for any time period.
We identified 4 articles that used rTMS as an accelerating 
strategy (ie, when both interventions were tested simultane-
ously to hasten antidepressant efficacy) for patients with 
treatment-resistant depression.25,74–76 In 2005, Rumi et al74 
investigated whether fast (5 Hz) rTMS combined with 
amitriptyline enhances the drug efficacy. In a sample of 
46 patients they demonstrated that the active group had a sig-
nificantly faster response when compared to the sham group. 
In a larger trial, with 99 patients, Rossini et al25 addressed 
whether fast (15 Hz) rTMS combined with venlafaxine, 
escitalopram or sertraline enhanced the drug response. They 
found statistically significant positive results for all drugs as 
compared to control (in this case drug and sham rTMS). In 
2007 a multi-center trial conducted by Herwig et al75 inves-
tigated the efficacy of add-on 10 Hz rTMS with mirtazapine 
or venlafaxine in 127 patients which showed similar rates 
of response (31%) for both active and sham groups. Finally, 
in 2008 Bretlau et al76 enrolled 45 patients to receive, either 
active or sham, fast rTMS combined with escitalopram and 
concluded that active treatment was superior to sham, with 
a large effect size of 0.70.
In a recent study Simpson et al addressed the cost-
effectiveness of rTMS in major depression using data from 
previous multi-center studies and of a Sequenced Treat-
ment Alternatives to Relieve Depression trial (STAR*D).77 Therapeutics and Clinical Risk Management 2009:5 904
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The authors modeled the cost-effectiveness of rTMS 
considering different scenarios in which rTMS was combined 
with antidepressants after failure in 1, 2, or more than 2 drug 
trials, and comparing such association with different augmen-
tation pharmacological strategies (antidepressant with mood 
stabilizer and atypical antipsychotic). Considering a base 
cost of US$300 per treatment session for rTMS, the authors 
demonstrated that rTMS is cost-effective considering QALY 
criteria and might be more cost-effective than determined 
psychopharmacological combinations.78
Discussion
The present study summarizes the main issues a clinician 
should consider on antidepressant use in major depression 
and other psychiatric disorders, ie, efficacy in acute-onset 
depression and in sustaining remission, tolerability in clinical 
practice – including safety and potential adverse effects, 
cost-effectiveness analysis, and an example of augmentation 
strategies using neurostimulation devices for patients failing 
to antidepressant trials.
Efficacy
The meta-analyses comparing drugs vs placebo showed 
antidepressants to be significantly superior to placebo, in 
both adult and geriatric patients with major depression 
in different clinical settings. The effects observed were 
consistent but modest. Kirsch et al15 compared drug-placebo 
difference vs baseline depression severity and found that 
it is clinically significant (ie, a 3-point difference) only in 
severe depression, suggesting that antidepressant use to 
be limited to this particular subgroup of patients. In a later 
rebuttal article, Kirsch79 comments further on the results of 
this meta-analysis. The main points being:
a)  The strong effect of placebo response that might be 
stronger for depression than for other disorders.
b)  The biased observation in clinical practice (one cannot 
differentiate the “pharmacological” part of the antide-
pressant drug response of the “nonpharmacological” 
response).
c)  The small advantage for drug over placebo shows that 
antidepressants have a lower effect than claimed.
Table 4 Characteristics of each repetitive transcranial magnetic study (rTMS) study included
Author Patients Strategy Antidepressant used Main results
Rossini25 99 accelerating venlafaxine, escitalopram  
or sertraline
rTMS hastened response  
of all drugs
Rumi74 46 accelerating Amitriptyline rTMS hastened response  
of drug
Herwig75 127 accelerating Mirtazapine or venlafaxine active and sham groups  
showed similar response
Bretlau76 45 accelerating escitalopram rTMS hastened response  
of drug
Su65 30 add-on various (TRD) superior response rate  
in active group
Rossini66 50 add-on various (TRD) superior response rate  
in the 100% MT group
Avery67 68 add-on various (TRD) superior response rate  
in active group
Fitzgerald68 50 add-on various (TRD) superior response rate  
in active group
Garcia-Toro69 30 add-on various (TRD) superior response rate  
in both active groups
Anderson70 29 add-on various (TRD) superior response rate  
in active group
Bortolomasi71 19 add-on various (TRD) superior response rate  
in active group
Loo72 38 add-on various (TRD) superior response rate  
in active group
Mogg73 59 add-on various (TRD) no difference between groups
Notes: An “accelerating” strategy is when both interventions begin at the same time, to hasten a response. An add-on strategy is when rTMS is used as an augmentation 
strategy.
Abbreviation: TRD, treatment-resistant depression.Therapeutics and Clinical Risk Management 2009:5 905
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d)  If the meta-analysis is based on flawed data, so are the 
trials that made drug approval possible.
Along these lines, Kirsch and Moncrieff80 defended 
the position that the choice of statistical methods greatly 
influence the outcomes, eg, using response rates instead of 
mean change scores can inflate the results.
Nevertheless, one should mindful that all meta-analyses 
of pooled results from efficacy studies (ie, clinical trials 
whose design is controlled through strategies of randomiza-
tion, double-blinding, and weekly visit) which are applied 
to a selected population that might not always be the same 
of clinical practice.17 Such controlled design favors high 
placebo rates that might diminish drug-placebo difference 
by a “ceiling” effect, also they are focused in increasing 
internal validity and not external generality of results, in 
other words, to address drug efficacy (the therapeutic effect 
in ideal, controlled circumstances) and not drug effectiveness 
(the therapeutic effect in usual, clinical settings).
Another important issue not addressed by these studies 
is the specificity of antidepressant effects, in other words, 
whether the amelioration associated with the use of these 
drugs is a specific effect associated with the mechanisms 
underlying major depression or a general effect on central 
nervous system. The effects of antidepressants on other 
conditions, such as generalized anxiety, panic disorder, 
obsessive-compulsive disorder, and chronic pain might favor 
the later hypothesis.
The meta-analyses of drug–drug trials did not show 
any drug to be particularly effective when performing only 
direct comparisons. It should be underscored that the meta-
analysis of Montgomery et al45 which found escitalopram to 
be definitely superior than other antidepressants, did not use 
important drugs such as sertraline, fluoxetine, paroxetine, and 
citalopram and thus such conclusions should be interpreted 
with care. In addition, Cipriani et al33 performing direct and 
indirect comparisons, observed that 4 drugs (mirtazapine, 
escitalopram, venlafaxine, sertraline) were superior to 
another 8 studied (buproprion, citalopram, duloxetine, 
fluoxetine, fluvoxamine, milnacipran, paroxetine, reboxetine). 
However, the authors also underscore the possibility of 
sponsorship bias, as 3 of the superior drugs are among the 
newest antidepressants (although meta-regression analysis 
did not confirm this possibility).
In addition, large pragmatic trials can also provide robust 
evidence for effectiveness. The STAR*D trial involved 
23 participating-psychiatric centers and 18 primary clinics 
and found no clear superior antidepressant in terms of effi-
cacy.21 Therefore, it seems that more than aiming for a specific 
“superior” antidepressant drug the clinician should focus on 
tolerability, adherence, and treatment compliance.
Tolerability
Therefore, a critical part of clinician strategy when dealing 
with major depression is to know, understand, and take 
advantage of the side effects profile each drug presents. 
For example, mirtazapine might not be the first choice for 
overweight patients, or paroxetine for patients with sexual 
dysfunction. The lack of studies covering breast-feeding 
and abnormalities in lipid metabolism cannot give definitive 
conclusions on the most suitable antidepressant, as there is 
no compelling evidence that antidepressants alter lipid levels 
independent of their effect on weight gain. Moreover, it is pos-
sible that lipid levels and major depression are positively 
correlated and independent of antidepressant use.81 Several 
antidepressants are known to pass into breast milk and thus 
to the baby; however, the evidence of safety is known for 
only a few drugs. Current guidelines recommend that the 
mother should take the antidepressant immediately after 
breastfeeding and prior to infant’s sleep time to minimize 
peak concentrations.82 Finally, although it seems that some 
drugs have less impact on sexual function than others 
(eg, sertraline and venlafaxine more than escitalopram or 
duloxetine) this adverse event is frequent and might be an 
important factor hampering compliance.54
The meta-analysis of Cipriani et al33 aimed to system-
atically assess not only the efficacy of antidepressants but 
also their profile of side effects indexing using dropout rate, 
assuming that dropouts observed in clinical trials occurred 
due to side effects. This might indeed be a viable measure-
ment, although other reasons could also have contributed to 
dropouts. In addition, no meta-analysis assessed patients’ 
long-term treatment compliance. It is known that compliance 
in major depression is poor: the average length of antidepres-
sant treatment is less than 6 months and 25% of patients do 
not inform their physician on stopping treatment.83 Therefore, 
although it is still unclear whether there is an antidepressant 
associated with a better compliance, some studies suggest 
that compliance might be influenced by time it takes for the 
antidepressant to take effect and the tolerability of an antide-
pressant, along with other associated factors such as patient 
education, therapeutic alliance, and family education.84,85
The observation that sertraline and escitalopram were 
among the most tolerated – and also the most effective 
– antidepressants might suggest that they are suitable for 
first-line treatment of depression. However, it should be 
underscored, within the limitations of this type of meta-analytic Therapeutics and Clinical Risk Management 2009:5 906
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approach, that in a large pragmatic trial (STAR*D) that 
compared sertraline vs bupropion vs venlafaxine in patients 
with major depression (after a failed citalopram trial), no 
difference between drugs was found in several outcomes 
(efficacy, response and remission rates and score change, time 
to remission, side effects, adverse effects, and dropouts). To 
our knowledge no large pragmatic trial has compared escitalo-
pram to other antidepressants, and therefore it should be kept 
in mind that the putative higher tolerability of escitalopram 
has yet to be tested in larger effectiveness trials.
Augmentation strategies
When antidepressant therapies fail, according to STAR*D, 
one third of patients remain clinically depressed after more 
than three failed trials.77 In fact the definition of “treatment-
resistant depression” varies, and although a recent review of 
clinical trials showed that such a concept is used to define a 
subgroup (15%–40%) of patients failing to achieve significant 
clinical improvement after at least two antidepressant trials,86 
other authors propose to quantify the degree of resistance77 
to better assess outcomes. Nevertheless, this subgroup of 
patients represents a particular challenge for the clinician, 
as response rates decay one level after each treatment fails,77 
thus demanding alternative strategies to manage depression 
symptoms. One option is the use of classic augmentation 
therapies, ie the combination of two antidepressants or 
one antidepressant combined to either lithium or thyroid 
hormone, as tested in the large pragmatic trial STAR*D. 
However, there is still room for improvement, considering 
other novel combination strategies, such as antidepressants 
associated with lamotrigine87 or atypical antipsychotics.88 
Another option is to combine antidepressants with neuro-
stimulation therapies, in our review we found that three of 
four trials and eight of nine trials showed positive results 
for rTMS as an add-on strategy and as an augmentation 
strategy, respectively. More studies are needed to determine 
whether or not there is a specific class of antidepressant that 
can achieve better results, and also in which populations this 
strategy should be targeted. However, considering the recent 
approval by the FDA for rTMS use in refractory depression 
and its virtually absence of side effects it is expected there 
will be an increasing interest for rTMS in the next years. 
Additionally tDCS might be another promising alternative, 
although the trial reviewed showed negative results another 
tDCS study enrolling drug-free patients (not included in this 
review) showed positive results: Boggio et al37 for instance, 
found fluoxetine and anodal tDCS to have similar efficacy 
in patients with major depression.
Pharmacoeconomics
The main agenda of the National Institute of Health in both 
the current and in the following years will be health care 
reform.89 One important issue being currently debated is 
whether universal health care coverage is possible and who 
will bear the costs; however it is clear that in order to achieve 
such a goal it is mandatory to spend resources in a controlled 
and organized way. Thus it will be increasingly important to 
the physician to evaluate the cost-effectiveness of a particular 
therapy. Unfortunately, pharmacoeconomics is a relatively 
new discipline and physicians together with health-policy 
makers are seldom trained on this field.90 The studies reviewed 
reflect the absence of consensus in methodology. While some 
studies rely on bayesian analyses, using data from clinical tri-
als, others studies aim to evaluate the impact of offering anti-
depressant drugs within the budget of local health systems. As 
a result, pharmacoeconomics study outcomes, in contrast to 
efficacy and tolerability studies, vary markedly from country 
to country, as important considerations, besides the drug 
cost itself, are its availability in local public health systems 
versus the availability of other antidepressants, the presence 
of generic brands, and also the overall costs of treatment 
(physician consultation, referral to specialist, hospitalization 
costs). Thus a drug economically suitable to use in one 
country might not be in another. Similarly, a study performed 
5 years ago might not be applicable currently due to market 
differences and the introduction of generics in the market. 
In this context, the use of neurostimulation techniques might 
be an economically viable alternative, rTMS for example 
Table 5 Summary of common side effects related to use of antidepressants
Side effect Drug Side effect Drug
Nausea/vomiting venlafaxine increase in blood pressure venlafaxine
Dizziness venlafaxine Somnolence Trazodone
Sexual side effects Sertraline, paroxetine, mirtazapine Discontinuation syndrome Paroxetine, venlafaxine
weight gain Mirtazapine, paroxetine Suicidal behavior Not enough evidence
Headache Bupropion Serotonin syndrome All antidepressants
insomnia Bupropion Drop-out rates Fluovoxamine, reboxetineTherapeutics and Clinical Risk Management 2009:5 907
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might be more cost-effective than augmentation with atypical 
antipsychotic drugs in treatment-resistant depression, and 
tDCS, if proved effective, might be an affordable alternative 
in underdeveloped countries.91 Therefore, although studies in 
pharmacoeconomics are currently methodologically inferior 
to the studies in efficacy, cost-effectiveness issues will prob-
ably increase in importance as public systems increase their 
participation in financing health care.
Limitations
In this review we assessed efficacy and tolerability of anti-
depressants by analyzing meta-analyses only. This is clearly 
a limitation as despite meta-analyses and systematic reviews 
often being considered the “best available evidence” they are 
dependant on the qualitative analysis of the trials included and 
the inclusion criteria of the meta-analyses used in our study.92 
Indeed meta-analyses vary with the inclusion of unpublished 
studies,15 sponsorship bias,93 and open-label studies.94 For 
example, a recent review of antidepressant publication bias95 
found that 94% of published trials were positive although 
when nonpublished trials are included only 51% were posi-
tive. In this study we included many meta-analyses in order to 
show results from studies using different inclusion criteria.
In this study the meta-analysis that found escitalopram and 
sertraline to be the most effective/tolerable antidepressant was 
determined through both direct and indirect comparisons.33 
An indirect comparison is made when drug A is compared 
to drug C by pooling the effects of the two (or more) studies, 
ie, one comparing drug A with drug B together with another 
studying drug B with drug C but without a trial comparing 
drug A directly with drug C. Although such an approach is 
justified when head comparison trials are limited,96 an indirect 
comparison considers a homogeneity assumption (patients 
belonging to the same population) as well as a similarity 
assumption (trials are similar for moderators of relative treat-
ment effect). A recent review97 of 88 meta-analyses using 
indirect comparisons, from 2000 to 2007, concluded that 
indirect comparisons can be unbiased if the assumptions of 
similarity and homogeneity are fulfilled; however further 
research on the topic is necessary. Within this context, meta-
analyses using indirect comparisons might be a good approach 
when synthesizing data of head-to-head noninferiority trials, 
as they might produce less biased results.98
Conclusion
Although recent meta-analyses suggest that the antidepres-
sants escitalopram and sertraline present the highest efficacy 
and tolerability rates among SSRIs and therefore should be 
regarded as first-line treatments for major depressive disorder, 
these findings were not observed in large pragmatic trials and 
in other meta-analyses using different statistical methods. 
Therefore, at the present time, neither meta-analyses nor large 
pragmatic trials provide robust evidence of superior efficacy 
for any specific antidepressant drug. More than trying to 
select the “superior” antidepressant the clinician should be 
aware of managing other aspects of antidepressant treatment, 
such as side effects, adverse effects, and pharmacological 
interactions. In fact, acknowledging the main side effects 
and tolerability of antidepressants allows physicians to tailor 
the most suitable drug for each patient. Cost-effectiveness 
issues should be kept in mind when adjusting these findings 
to local settings. Finally, when the depressed patient fails to 
respond to an antidepressant trial, other available options 
are to switch to another antidepressant, augment the treat-
ment with an additional antidepressant, or uptitrate the drug 
dosage. Another alternative is to associate antidepressants 
with neuromodulation interventions, eg, ECT is a powerful 
augmentation strategy to treat depression, although associ-
ated with cognitive impairment in some cases, while rTMS 
has moderate efficacy yet it is virtually free of side effects, 
and further studies are necessary to address the role of tDCS 
in the treatment of major depression.
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